| Nome |
# |
|
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato?, file e31e10d2-4a26-31fb-e053-1705fe0a5b99
|
406
|
|
Esiti di salute e performance del Servizio Sanitario Nazionale, file e31e10d4-1a29-31fb-e053-1705fe0a5b99
|
348
|
|
Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international Health Technology Assessment agencies, file e31e10d4-5a9c-31fb-e053-1705fe0a5b99
|
210
|
|
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters, file e31e10d4-397e-31fb-e053-1705fe0a5b99
|
192
|
|
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione?, file e31e10d2-94b9-31fb-e053-1705fe0a5b99
|
191
|
|
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci, file e31e10d3-8f97-31fb-e053-1705fe0a5b99
|
188
|
|
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies, file e31e10d4-4fb9-31fb-e053-1705fe0a5b99
|
177
|
|
Gli esiti di salute del Servizio Sanitario Nazionale, file e31e10d3-94ff-31fb-e053-1705fe0a5b99
|
176
|
|
Dinamiche economiche e performance del settore dei dispositivi medici in Italia, file e31e10d3-e3f9-31fb-e053-1705fe0a5b99
|
176
|
|
Value lies in the eye of the patients: the why, what, and how of patient-reported outcomes measures, file e31e10d3-cb31-31fb-e053-1705fe0a5b99
|
159
|
|
Gli esiti di salute del Servizio Sanitario Nazionale, file e31e10d3-9500-31fb-e053-1705fe0a5b99
|
152
|
|
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations, file 792cb41f-4106-4a1a-baa9-e90c3ed9e992
|
151
|
|
Esiti di salute e performance del Servizio Sanitario Nazionale, file a7982d94-7008-4faf-b82c-ee0c5acb90bd
|
148
|
|
Distinguishing features in the assessment of mHealth apps, file e31e10d4-4dcc-31fb-e053-1705fe0a5b99
|
146
|
|
Gli esiti di salute del Servizio Sanitario Nazionale, file e31e10d3-11cb-31fb-e053-1705fe0a5b99
|
136
|
|
Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective, file e31e10d4-1b28-31fb-e053-1705fe0a5b99
|
135
|
|
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps, file e31e10d4-9bda-31fb-e053-1705fe0a5b99
|
121
|
|
The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this?, file e31e10d4-75ea-31fb-e053-1705fe0a5b99
|
118
|
|
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide, file 34b2ed3b-4fce-4f63-9146-7aeafc974b5d
|
115
|
|
Esiti di salute e performance del Servizio Sanitario Nazionale, file e31e10d3-d7f9-31fb-e053-1705fe0a5b99
|
100
|
|
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis, file e31e10d3-a475-31fb-e053-1705fe0a5b99
|
80
|
|
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer, file e31e10d3-cb33-31fb-e053-1705fe0a5b99
|
77
|
|
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci, file e31e10d3-8f03-31fb-e053-1705fe0a5b99
|
74
|
|
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal, file e31e10d4-624f-31fb-e053-1705fe0a5b99
|
61
|
|
Raising the bar for using surrogate endpoints in drug regulation and health technology assessment, file e31e10d4-6b9f-31fb-e053-1705fe0a5b99
|
60
|
|
Response to COVID-19: was Italy (un)prepared?, file e31e10d4-615a-31fb-e053-1705fe0a5b99
|
52
|
|
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study, file e31e10d3-e3b5-31fb-e053-1705fe0a5b99
|
45
|
|
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials, file e31e10d4-73f0-31fb-e053-1705fe0a5b99
|
45
|
|
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration, file e31e10d4-75eb-31fb-e053-1705fe0a5b99
|
45
|
|
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany, file e31e10d2-e165-31fb-e053-1705fe0a5b99
|
43
|
|
Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers, file 50a9d7b1-8a31-4cf4-9e31-9c4d310908af
|
42
|
|
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato?, file e31e10d2-7b85-31fb-e053-1705fe0a5b99
|
40
|
|
EQ-5D-5L population norms for Italy, file f4b347a1-e27b-4530-9dbb-da683dc4a07a
|
37
|
|
Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence, file e31e10d4-9f5f-31fb-e053-1705fe0a5b99
|
34
|
|
Quo vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges, file e31e10d4-4dce-31fb-e053-1705fe0a5b99
|
33
|
|
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy., file e31e10d4-621d-31fb-e053-1705fe0a5b99
|
30
|
|
Surrogate endpoints in health technology assessment: an international review of methodological guidelines, file e31e10d4-65ee-31fb-e053-1705fe0a5b99
|
30
|
|
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges, file e31e10d4-5edb-31fb-e053-1705fe0a5b99
|
29
|
|
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments, file e31e10d4-4dd0-31fb-e053-1705fe0a5b99
|
27
|
|
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database, file cf1c2aa7-89d9-49dd-97d7-f23332d72814
|
26
|
|
Surrogate endpoints in trials-a call for better reporting, file aa0fd167-09dc-45d7-9233-0b665dcd7101
|
24
|
|
Lung cancer stage distribution from before COVID-19 through 18 months of the pandemic: the experience of a large-volume oncological referral centre, file e31e10d4-7630-31fb-e053-1705fe0a5b99
|
24
|
|
Coverage with evidence development for medical devices in Europe: can practice meet theory?, file e31e10d4-9aa1-31fb-e053-1705fe0a5b99
|
24
|
|
Disability weights for castration-resistant prostate cancer : an empirical investigation, file d93d1e0b-4cfb-4761-85ba-96d1ee32edc4
|
23
|
|
A call for better reporting of trials using surrogate primary endpoints, file bde579b9-54e2-48b3-813f-9caa65ef44a1
|
21
|
|
The Net Benefit of a treatment should take the correlation between benefits and harms into account, file e31e10d4-5a9a-31fb-e053-1705fe0a5b99
|
21
|
|
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study, file e31e10d4-876a-31fb-e053-1705fe0a5b99
|
21
|
|
Editorial: Near-infrared fluorescence guided surgery: state of the evidence from a health technology assessment perspective, file 853cb46a-1b68-4300-b5c0-090708de92b7
|
20
|
|
Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE, file 9520f570-e6fe-4cd4-b60b-d6df197c3005
|
20
|
|
Commentary: Nothing but a toothbrush for beginning the reduction of the postoperative costs in thoracic surgery, file fb3d864f-270a-440c-8c44-9f306f5e232f
|
19
|
|
Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions, file 03d92512-7454-4613-9873-3395103007c7
|
18
|
|
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer, file e31e10d3-7455-31fb-e053-1705fe0a5b99
|
18
|
|
Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol, file 5f8839ce-d753-45f5-b023-08b39b8f3c89
|
16
|
|
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy, file f2de3b15-133e-4ac1-b2ae-86fbb8a0ae62
|
16
|
|
Evaluating the ability of an artificial-intelligence cloud-based platform designed to provide information prior to locoregional therapy for breast cancer in improving patient's satisfaction with therapy: the CINDERELLA trial, file 0db60683-e082-4b22-a0bf-c22fa93ddaf9
|
13
|
|
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems?, file e31e10d2-1fd3-31fb-e053-1705fe0a5b99
|
13
|
|
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?, file 156bfc50-3f5b-4651-914a-a5d0ae381865
|
11
|
|
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy, file b419824d-3a3a-46a3-a3af-fd14f93e8c8c
|
11
|
|
An economic perspective on urinary tract infection: the "costs of resignation", file e31e10d2-20d6-31fb-e053-1705fe0a5b99
|
11
|
|
Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review, file f2ed7ab5-e450-4d1f-b64c-70bf4ddf6571
|
11
|
|
The assessment of patient-reported outcomes for the authorisation of medicines in Europe: a review of European Public Assessment Reports from 2017 to 2022, file 25b583b1-605f-47f8-a93e-93cb1c4e604a
|
10
|
|
The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy, file abfaa442-ad6a-4578-9258-ebacf2b12780
|
8
|
|
Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review, file ebf5bd4b-cdc1-4934-a2a2-23908b72d18e
|
8
|
|
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials, file 781bcfa5-46a1-4d01-8885-4458b2b44f3f
|
6
|
|
Comparing drug and non-drug technologies in comparative effectiveness research, file e31e10d2-57cc-31fb-e053-1705fe0a5b99
|
6
|
|
Measuring value in health care: a comparative analysis of value-based frameworks, file e31e10d3-cb35-31fb-e053-1705fe0a5b99
|
6
|
|
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices, file e31e10d4-002a-31fb-e053-1705fe0a5b99
|
6
|
|
Surrogate endpoints: a key concept in clinical epidemiology, file 011ea1f3-fadb-4caf-a1ae-ed1d2422e11e
|
5
|
|
Comparing drug and non-drug technologies in comparative effectiveness research, file e31e10d2-57cb-31fb-e053-1705fe0a5b99
|
4
|
|
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis, file e31e10d2-811a-31fb-e053-1705fe0a5b99
|
4
|
|
The impacts of diabetes research from 31 European Countries in 2002 to 2013, file e31e10d3-36a3-31fb-e053-1705fe0a5b99
|
4
|
|
The rise of rules: will the new regulation of medical devices make us safer?, file e31e10d3-ff5c-31fb-e053-1705fe0a5b99
|
4
|
|
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani, file e31e10d2-1df1-31fb-e053-1705fe0a5b99
|
3
|
|
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie, file e31e10d2-2154-31fb-e053-1705fe0a5b99
|
3
|
|
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses, file e31e10d2-7a83-31fb-e053-1705fe0a5b99
|
3
|
|
Current and Future Trends in the HTA of Medical Devices, file e31e10d2-7b1a-31fb-e053-1705fe0a5b99
|
3
|
|
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial, file e31e10d2-865a-31fb-e053-1705fe0a5b99
|
3
|
|
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials, file e31e10d3-52d5-31fb-e053-1705fe0a5b99
|
3
|
|
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective, file e31e10d3-52d7-31fb-e053-1705fe0a5b99
|
3
|
|
Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms, file e31e10d3-52d9-31fb-e053-1705fe0a5b99
|
3
|
|
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials, file e31e10d3-5328-31fb-e053-1705fe0a5b99
|
3
|
|
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati, file e31e10d3-e77a-31fb-e053-1705fe0a5b99
|
3
|
|
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices, file e31e10d4-002b-31fb-e053-1705fe0a5b99
|
3
|
|
Core outcome set in surgical oncology: why, what and how to measure, file e31e10d4-1d74-31fb-e053-1705fe0a5b99
|
3
|
|
The Coronavirus pandemic and inequality in Italy, file 1bf9c600-b074-4f3c-905c-a48ba85c8b05
|
2
|
|
Implementing preconception expanded carrier screening in a universal healthcare system: a model-based cost-effectiveness analysis, file 24d7c4fc-9323-493b-a3ab-8c9c0c404057
|
2
|
|
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making, file e31e10d2-564c-31fb-e053-1705fe0a5b99
|
2
|
|
Time to review the role of surrogate end points in health policy: state of the art and the way forward, file e31e10d2-ad5c-31fb-e053-1705fe0a5b99
|
2
|
|
European diabetes research and its funding, 2002–2013, file e31e10d2-d2df-31fb-e053-1705fe0a5b99
|
2
|
|
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma, file e31e10d2-f680-31fb-e053-1705fe0a5b99
|
2
|
|
Broadening the concept of value: a scoping review on the option value of medical technologies, file e31e10d4-6101-31fb-e053-1705fe0a5b99
|
2
|
|
The importance of using the appropriate model for systematic reviews and meta-analyses-reply, file e31e10d4-9e08-31fb-e053-1705fe0a5b99
|
2
|
|
Strumenti a supporto del processo decisionale condiviso in oncologia, file 64a5c3f7-a66d-46a6-bd6c-1bdec03d22d3
|
1
|
|
Surrogate end points in cardio-thoracic trials: a call for better reporting and improved interpretation of trial findings, file cabcb187-26c5-45dd-8658-29c85f4eec8b
|
1
|
|
Which behaviour change techniques work best for diabetes self-management mobile apps? Results from a systematic review and meta-analysis of randomised controlled trials, file cbb7982d-3a8f-4f1a-bf0e-fd55f71fdfbf
|
1
|
|
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia, file e31e10d2-23cc-31fb-e053-1705fe0a5b99
|
1
|
|
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese, file e31e10d2-23cd-31fb-e053-1705fe0a5b99
|
1
|
|
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study, file e31e10d2-7b4b-31fb-e053-1705fe0a5b99
|
1
|
|
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework, file e31e10d2-8f80-31fb-e053-1705fe0a5b99
|
1
|
|
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement, file e31e10d2-a28a-31fb-e053-1705fe0a5b99
|
1
|
| Totale |
4.941 |